Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

MENTOR Metabolic control of cell growth by mTOR in health and disease: a multi-disciplinary training

Coordinator
Universite Paris Cite, France
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€4.0m
Total cost
—
Partners
26 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168624

What the project is doing

In the project's own words, from its summary on CORDIS.

MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cues and controls cell growth and metabolism. Aberrant activation of mTOR underlies monogenic diseases with broad spectrum of pathological manifestations, including tissue overgrowth, polycystic kidneys and neuropsychiatric disorders affecting around two million of people worldwide. To avoid the medical errancy of patients in different clinical departments and surgical mutilations, approaches of personalized medicine depending on the genetic landscape need to be implemented, taking advantage of suitable pharmacological products.

The overall goal of the MENTOR research program is to: delineate molecular mechanisms of fundamental and aberrant mTOR functions, preclinically decipher the pathophysiology of mTOR, develop a novel arsenal of drugs to selectively target the pathway and provide proof-of-concept support for such interventions. This ambition can only be achieved by the multidisciplinary research program that MENTOR has conceived, through the training of a new generation of scientists at Graduate Schools of biology, pharmacy, chemistry or medicine that will become the leaders of mTOR research in both public and private sectors.

MENTOR will establish a collaborative and efficient network from academia to industry, involving patient associations and clinicians with impact on scientific community and society.

Topics

Who is involved

OrganisationCityCountryRole
Universite Paris CiteParisFranceCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Topadur Pharma AGSchlierenSwitzerlandAssociatedpartner
Universitat BaselBaselSwitzerlandAssociatedpartner
Universite De FribourgFribourgSwitzerlandAssociatedpartner
Biosolveit GmbHSankt AugustinGermanyAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
European Tuberous Sclerosis Complex Association (e-tsc)WiesbadenGermanyAssociatedpartner
Universitaetsklinikum EssenEssenGermanyParticipant
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Panepistimio IoanninonIoanninaGreeceAssociatedpartner
Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos IiiMadridSpainParticipant
Universidad Autonoma De MadridMadridSpainAssociatedpartner
Assistance Publique Hopitaux De ParisParisFranceAssociatedpartner
Institut Du Cerveau Et De La Moelle EpiniereParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceAssociatedpartner
Sorbonne UniversiteParisFranceAssociatedpartner
Fondazione Telethon EtsRomaItalyParticipant
Universita Degli Studi Di Napoli Federico IiNapoliItalyAssociatedpartner
Mimetas BVLeidenNetherlandsParticipant
Pd-Value BVHoutenNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej W WarszawieWarszawaPolandAssociatedpartner
Miedzynarodowy Instytut Mechanizmow I Maszyn Molekularnych Polskiej Akademii NaukWarszawaPolandParticipant
The Myrovlytis TrustLondonUnited KingdomAssociatedpartner
Cell Signaling Technology, Inc.DanversUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI